# Survodutide

A weekly injection that pairs GLP-1 with glucagon, which makes the liver burn more fat. Weight loss is moderate; the bigger hope is fatty liver disease.

Also called: BI 456906
Source page: https://peplogue.com/peptides/survodutide/
Reviewed: 2026-10-12. Not medical advice.

## How it works

- Where it acts: Glucagon and GLP-1 receptors.
- What it changes: GLP-1 lowers appetite. Glucagon pushes the liver to burn fat.
- What people notice: Moderate weight loss and less liver fat in trials. Nausea and vomiting are common.

## What the evidence shows

- **Weight loss in obesity**: Supported. SYNCHRONIZE-1 (76 weeks): 16.6% on the 6 mg dose, against 3.2% on placebo. In type 2 diabetes, up to 13.1% against 3.1% (SYNCHRONIZE-2).
- **Fatty liver disease (MASH)**: Supported. In phase 2, MASH improved in up to about 6 in 10 people, against about 1 in 7 on placebo. Two phase 3 liver trials are running.

## Side effects and risks

- common: Stomach side effects drove 18% to 20% of people to stop in the main obesity trial, against 3% on placebo, a higher rate than the approved drugs showed in their own trials.
- unknown: Its effect on heart attacks and strokes is unknown until the outcomes trial reports.

Who should avoid it: Anyone outside a clinical trial.

## How it has been given in trials

Weekly injection under the skin, raised in steps to 3.6 mg or 6 mg. There is no approved dose.

## Legal status

- United States: undefined. No filing announced.
- European Union: undefined
- Spain: undefined. Investigational. No authorised product in Spain (not in CIMA). The only lawful route is a clinical trial; Spanish trial sites not verified.
- Germany: undefined. Not authorised in Germany. Only available in clinical trials; sale outside trials is unlawful under the AMG (§ 21, § 96). German trial sites not checked.
- France: undefined. Investigational drug, not authorised in France. Only lawful route is a trial; ANSM says peptides bought outside the official circuit are illegal.
- Italy: undefined. Investigational. Not authorised in the EU or Italy; only reachable through a clinical trial. Italian trial sites not checked.
- Netherlands: undefined. Experimental. No marketing authorisation in the Netherlands or EU; only in clinical trials. Offering it as a medicine without authorisation is illegal.
- United Kingdom: undefined
- Canada: undefined
- Australia: undefined

## Questions people ask

**How does survodutide work?**

It is a weekly injection that pairs GLP-1, which lowers appetite, with glucagon, which pushes the liver to burn fat.

**How much weight loss does survodutide cause?**

In SYNCHRONIZE-1, people on the higher dose lost 16.6% at 76 weeks, against 3.2% on placebo. In type 2 diabetes the figure was up to 13.1%, against 3.1%.

**Does survodutide help fatty liver disease?**

In phase 2, MASH improved in up to about 6 in 10 people, against about 1 in 7 on placebo. Two phase 3 liver trials are running.

**What are the side effects of survodutide?**

Stomach side effects drove 18% to 20% of people to stop in the main obesity trial, against 3% on placebo. Its effect on heart attacks and strokes is unknown until the outcomes trial reports.

**Is survodutide approved?**

No. No US filing has been announced, and a cardiovascular outcomes result is due by the end of 2026.

## Sources

- AJMC: survodutide SYNCHRONIZE-2 results (1 Oct 2026): https://www.ajmc.com/view/dual-agonist-survodutide-delivers-up-to-13-1-weight-loss-in-t2d
- Zealand Pharma: half-year results 2026: https://www.inderes.dk/en/releases/zealand-pharma-announces-financial-results-for-the-first-half-of-2026